1332075-40-7

1332075-40-7 structure

1332075-40-7 structure

Name: Tirofiban-d9
Chemical Name: Tirofiban-d9
CAS Number: 1332075-40-7
Molecular Formula: C₂₂H₂₇D₉N₂O₅S
Molecular Weight: 449.65
Catalog: Signaling Pathways Cytoskeleton Integrin
Create Date: 2022-06-16 09:51:13
Modify Date: 2024-04-05 21:26:16
Tirofiban-d9 is deuterium labeled Tirofiban.

Name	Tirofiban-d9

Description	Tirofiban-d9 is deuterium labeled Tirofiban.
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> Cytoskeleton >> Integrin
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Winter JP, Juergens CP. The role of tirofiban in the management of coronary artery disease. Cardiovasc Hematol Disord Drug Targets. 2008 Jun;8(2):138-46. [3]. van 't Hof AW, Valgimigli M. Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban. Drugs. 2009;69(1):85-100. [4]. Valgimigli M, Biondi-Zoccai G, Tebaldi M et al. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J. 2010 Jan;31(1):35-49. [5]. Valgimigli M, Tebaldi M. Safety evaluation of tirofiban. Expert Opin Drug Saf. 2010 Sep;9(5):801-19. [6]. Diaz JF, Cardenal R, Gomez-Manchero A, Sanchez-Gonzalez C. Safety and efficacy of tirofiban as adjunctive therapy for patients with ST-elevation myocardial infarction: a comparison versus placebo and abciximab. Cardiovasc Hematol Agents Med Chem. 2011 Jul 1;9(3):147-53.

Molecular Formula	C₂₂H₂₇D₉N₂O₅S
Molecular Weight	449.65